| P50 | author | Gary Nabel | Q29446276 |
| P2860 | cites work | Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein | Q24563514 |
| | Prospective identification of tumorigenic breast cancer cells | Q24683474 |
| | Continuous cultures of fused cells secreting antibody of predefined specificity | Q26776979 |
| | Core structure of gp41 from the HIV envelope glycoprotein | Q27736064 |
| | Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 |
| | LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 |
| | Bone marrow cells regenerate infarcted myocardium | Q28210640 |
| | Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy | Q28215190 |
| | Rapid evolution of a protein in vitro by DNA shuffling | Q28245873 |
| | DNA shuffling of a family of genes from diverse species accelerates directed evolution | Q28259708 |
| | Dendritic cells: specialized and regulated antigen processing machines | Q29617085 |
| | Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines | Q33757015 |
| | Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant | Q33762569 |
| | T-cell receptors for cytokines: targets for immunotherapy of leukemia/lymphoma | Q33857087 |
| | a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 |
| | Immunization for Ebola virus infection | Q34065766 |
| | Therapeutic antibodies for human diseases at the dawn of the twenty-first century | Q34168125 |
| | Adalimumab (HUMIRA): a review. | Q34217586 |
| | Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines | Q34302502 |
| | Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans | Q34345458 |
| | Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction | Q34354588 |
| | Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial | Q34530459 |
| | One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. | Q34582606 |
| | Gene silencing in mammals by small interfering RNAs | Q34931992 |
| | Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning | Q34932593 |
| | Immune therapy for EBV infections after hemopoietic stem-cell transplant | Q35020998 |
| | Natural versus adaptive regulatory T cells | Q35092554 |
| | A clinical and scientific overview of tositumomab and iodine I 131 tositumomab | Q35120247 |
| | Therapeutic strategies for rheumatoid arthritis | Q35140855 |
| | Clinical trials of transplant tolerance: slow but steady progress | Q35157558 |
| | Newer aspects in the treatment of pediatric and adult asthma: monoclonal anti-IgE. | Q35168245 |
| | Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept. | Q35173724 |
| | Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer | Q35177848 |
| | Rituximab in B-cell chronic lymphocytic leukemia | Q35206360 |
| | Adoptive-cell-transfer therapy for the treatment of patients with cancer | Q35210008 |
| | Hope for a broken heart? | Q35541459 |
| | Eotaxin Receptor (CCR3) Antagonism in Asthma and Allergic Disease | Q35560644 |
| | The role of cytokines in immunological tolerance: potential for therapy | Q35571072 |
| | Islet cell transplantation for insulin-dependent diabetes mellitus: perspectives from the present and prospects for the future | Q35571079 |
| | Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals | Q35800195 |
| | DNA vaccination against persistent viral infection. | Q35838136 |
| | Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity | Q36366362 |
| | Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients | Q37679611 |
| | DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. | Q39869845 |
| | Cellular Adoptive Immunotherapy after Bone Marrow Transplantation | Q40424152 |
| | The safety and immunogenicity of a CETP vaccine in healthy adults | Q40574796 |
| | DNA immunization protects nonhuman primates against rabies virus | Q40846902 |
| | Vaccination against tuberculosis by DNA injection | Q41182163 |
| | Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector | Q41192415 |
| | DNA vaccines against malaria: immunogenicity and protection in a rodent model | Q41264979 |
| | Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27. | Q41384448 |
| | Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. | Q41722852 |
| | Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver | Q41753510 |
| | T cell therapy of human CMV and EBV infection in immunocompromised hosts | Q43470154 |
| | Genetic modification of T-cell clones for therapy of human viral and malignant diseases. | Q43696495 |
| | Heterologous protection against influenza by injection of DNA encoding a viral protein | Q43828996 |
| | Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation | Q44027111 |
| | Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia | Q44143782 |
| | A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency | Q45857796 |
| | Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T Cells | Q46025217 |
| | Applied evolution. The progeny of sexual PCR. | Q54629038 |
| | Gene transfer as an approach to treating hemophilia | Q64377890 |
| | Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart | Q64379356 |
| | The future of gene therapy | Q73741937 |
| | Adalimumab | Q73896817 |
| | Development of anti-TNF therapy for rheumatoid arthritis | Q74187188 |
| | Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis | Q74290884 |
| | Vaccines: ideal drugs for the 21st century? | Q74436852 |
| | DNA vaccines | Q93896322 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 135-141 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Genetic, cellular and immune approaches to disease therapy: past and future | |
| P478 | volume | 10 | |